Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The first participant in the RIDD trial – which is testing whether anti-TNF therapy can prevent or slow the progression of Dupuytren’s disease - has received their trial injection. Dupuytren’s disease affects 4% of the general UK population and causes the fingers to curl irreversibly into the palm. There is currently no approved treatment to prevent disease progression.

 The RIDD trial has two parts – our first participant is taking part in the dose response study for patients with advanced disease who are due to have the diseased tissue surgically removed. We will analyse the removed tissue in the lab to see the effect the treatment has had on the cells. The other part of the RIDD trial is for patients with early disease – with nodules in their hand but only mild or no contracture – and this will open in the summer. 

Similar stories

Celebrating Clinical Trials Day at NDORMS

To mark Clinical Trials Day we take a look at some of the recent developments at NDORMS and celebrate the teams that make this important area of our research programme possible.

Breakthrough in treatment for Dupuytren’s disease

Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.

Liposomal bupivacaine found to be no more effective than current treatments for post-operative knee pain

A new study published in JAMA, has found that a drug recently licensed in the UK has no effect on post-operative knee replacement recovery or pain, compared to the current treatment when administered at site of surgery.

Cemented hip replacement improves quality of life for patients over 60

The White 5 trial compared implants fixed with bone cement against uncemented implants for hip fractures treated with hemiarthroplasty.

FUTURE-GB looking ahead to 2022

FUTURE-GB has bounced into 2022 ahead of both predicted recruitment into Stage 2 (the Randomised Controlled Trial), and the sites open in Stage 2! Congratulations to all our sites for their hard work so far.